Weekly Headlines | May 13th

May 13, 2022
Headlines

Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.


Markets

Performance of psychedelic public companies this past week.


Company News

MindMed ($MMED | $MDNMD) provided positive results from their Phase II clinical trial focused on LSD as a potential treatment for anxiety disorders. The data demonstrated significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression. Press Release

Wesana Health Holdings ($WESA) successfully completed their Pre-IND meeting with the FDA. Wesana Health is expanding their lead indication for SANA-013 to Major Depressive Disorder and exploring other complementary orphan indications. Press Release

Cybin ($CYBN) announced pilot results from a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure cortical hemodynamics while experiencing an altered state of consciousness. Preliminary data from the study suggested that ketamine-induced changes in functional connectivity persisted for several days after administration. Press Release

Field Trip Health ($FTRP) launched Field Trip at Home with Nue Life, a leader in mental wellness telehealth and at-home ketamine treatments. Field Trip at Home is an advanced wellness platform for personalized, at-home psychedelic care. Press Release

Novamind ($NM | $NVMDF) has been selected to host a clinical trial for the acute treatment of social anxiety disorder. The Phase II randomized study is sponsored by Bionomics Ltd and will examine the safety and efficacy of their propriety drug candidate. Press Release

Wellbeing Digital Sciences ($MEDI) became a founding sponsor of the Women in Psychedelics Network. WIP was created to bring women together in the psychedelic industry and build a community based on education, support, growth, and experience. Press Release

Optimi Health ($OPTI | $OPTHF) completed a planned expansion of the on-site analytical laboratory at their British Columbia facility. The state-of-the-art indoor growing facilities is dedicated to the cultivation of safe, high-quality psychedelic and functional mushrooms. Press Release

COMPASS Pathways ($CMPS) will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults. This will be the first ever mechanistic study of psilocybin in autistic adults. Press Release

Nova Mentis Life Science ($NOVA | $NMLSF) appointed Board Certified Behaviour Analyst specializing in autism spectrum disorder therapy John Molinaro to their Scientific Advisory Board. Press Release


Media

Psychedelic Finance: Interview With Daniel Carcillo Of Wesana Health

The Guardian: Europe’s First Psychedelic Drug Trial Firm To Open In London

Forbes: Shark Tank’s Kevin Harrington Invests In Psychedelics Company

The Times: Scientists Are Once Again Tuning In To Use Of Psychedelics

CBS: Therapists Talk Medical Advantages For Psychedelic Drugs For Patients

Bloomberg: Inventor of Brain-Scan Helmet Takes Ketamine to Test His Technology

Fast Company: The Next Frontier of Psychedelic Therapy Could Be Your Couch


Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.